CU Researchers Develop Key Findings as COVID-19 Clinical Trials Progress


CU Anschutz and CCTSI play a key role in developing antiviral medications and working to attenuate the inflammatory response.

In just a few months, physicians have developed key findings through multiple clinical trials at CU Anschutz, testing previously FDA-approved drugs and new medications to battle COVID-19.

“Two months ago I would not have guessed we’d have encouraging results so quickly,” says Tom Campbell, MD, professor of infectious disease at the School of Medicine, who is leading many of the trials. “It makes it all the more exciting for those of us who are helping out with the effort.”

CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process